All PlansPrior AuthMedium impact
Interferons (CPB 0404, reviewed 2026-06-09)
Aetna·Hematology, Oncology, Endocrinology +2 more·Medical Policy
Effective date
Jun 9, 2026
We identified it
Aug 16, 2026
Summary
Aetna updated its Interferons medical policy (CPB 0404) effective June 9, 2026, clarifying coverage criteria for three interferon medications: interferon gamma-1b (Actimmune), peginterferon alfa-2a (Pegasys), and ropeginterferon alfa-2b-njft (Besremi). The policy specifies which specialties must prescribe each medication, defines approved indications with strict parameters (e.g., peginterferon alfa-2a for chronic hepatitis B limited to 48 weeks), and establishes continuation criteria based on documented clinical response. All other indications are deemed experimental/investigational.
Action Required
By June 9, 2026: Billing team must update prior authorization workflows to enforce specialist-based prescribing requirements (immunologist for CGD with Actimmune, endocrinologist for SMO with Actimmune, hematologist/oncologist for mycosis fungoides with Actimmune). Configure system to flag and deny claims from non-approved specialists. For peginterferon alfa-2a (Pegasys), implement 48-week treatment limit for chronic hepatitis B with automated denial after this threshold. For ropeginterferon alfa-2b-njft (Besremi), restrict myeloproliferative neoplasm and systemic mastocytosis indications to cases where Pegasys is unavailable. Require supporting documentation for all continuation authorizations demonstrating disease stability or improvement per defined criteria (e.g., morphological response, reduction in spleen size, improvement of metabolite markers). Update encounter forms and prior auth templates to reflect approved indications only; deny all off-label uses as experimental. Train billing staff and providers on specialty prescriber restrictions to prevent claim denials.